For patients who undergo adalimumab tapering after achieving remission, factors such as age, race, and duration of disease remission on adalimumab appear to impact the risk of relapse, according to a study.
Treatment with brolucizumab results in a longer interval between injections of antivascular endothelial growth factor (anti-VEGF) agents for most treatment-experienced eyes, especially those with shorter intervals before switching, while maintaining or improving visual acuity (VA), reports a study.
Retinopathy of prematurity (ROP) appears to be the leading cause of childhood blindness, reveals a recent study in the US. More than half of these blind patients have had a treatable cause of blindness.
High glaucoma polygenic risk score (PRS) shows a significant association with earlier initiation or escalation of intraocular pressure (IOP)-lowering therapy, according to a study, noting the potential usefulness of genetic risk stratification in glaucoma.
In patients with neovascular age-related macular degeneration (nAMD) who switched to brolucizumab treatment, those with shorter treatment interval before switching are more likely to have successful injection interval extension, as shown in a study.
Brolucizumab helps improve visual and anatomic outcomes in diabetic macular edema (DME), with long-term efficacy and durability and no new safety signals, as shown in the 100-week data from the phase III KESTREL and KITE studies.
Less amblyopic individuals are more likely to have age-related macular degeneration (AMD) diagnosed on the amblyopic eye than on the nonamblyopic eye, as reported in a study. Meanwhile, individuals with lateral asymmetry tend to have the more advanced form of AMD on the nonamblyopic eye.